Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.

IF 3.6 3区医学 Q2 PHARMACOLOGY & PHARMACY

Expert Review of Clinical Pharmacology Pub Date : 2024-11-25 DOI:10.1080/17512433.2024.2433603

Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla

{"title":"Risk of new onset diabetes mellitus with pitavastatin as compared to atorvastatin and rosuvastatin: a systematic review and meta-analysis.","authors":"Harmanjit Singh, Sangambir Kaur, Parul Kaushal, Jatin Sharma, Mandeep Singla","doi":"10.1080/17512433.2024.2433603","DOIUrl":null,"url":null,"abstract":"Background: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often associated with NODM, pitavastatin may carry a lower risk. This systematic review and meta-analysis (SRMA) evaluated the impact of pitavastatin on NODM compared to atorvastatin and rosuvastatin.Methods: We conducted a systematic literature search using PubMed, CENTRAL, EMBASE, and ClinicalTrials.gov. Two authors independently screened studies, assessed the risk of bias using Joanna Briggs Institute, Newcastle-Ottawa, and Scottish Intercollegiate Guidelines Network checklists, and extracted data. The analysis was performed using RevMan 5.4.1, and results were represented as risk ratios (RR) with 95% confidence intervals (CI) and heterogeneity was evaluated using the I2 statistic.Results: Of 517 records screened, 13 studies were included, comprising observational studies, and randomized controlled trials. Most of the studies showed pitavastatin to be associated with a lower or no risk of NODM. Meta-analysis revealed that pitavastatin had a lower risk of NODM compared to atorvastatin (RR = 0.86, 95% CI = 0.79-0.93, p = 0.0002) and rosuvastatin (RR = 0.77, 95% CI = 0.71-0.84, p < 0.00001).Conclusion: Pitavastatin poses a lower risk of NODM than other statins, making it a potentially safer option for patients requiring long-term statin therapy.Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42022371741.","PeriodicalId":12207,"journal":{"name":"Expert Review of Clinical Pharmacology","volume":" ","pages":"1-9"},"PeriodicalIF":3.6000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17512433.2024.2433603","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Statins are linked to the risk of new-onset diabetes mellitus (NODM). While atorvastatin and rosuvastatin are often associated with NODM, pitavastatin may carry a lower risk. This systematic review and meta-analysis (SRMA) evaluated the impact of pitavastatin on NODM compared to atorvastatin and rosuvastatin.

Methods: We conducted a systematic literature search using PubMed, CENTRAL, EMBASE, and ClinicalTrials.gov. Two authors independently screened studies, assessed the risk of bias using Joanna Briggs Institute, Newcastle-Ottawa, and Scottish Intercollegiate Guidelines Network checklists, and extracted data. The analysis was performed using RevMan 5.4.1, and results were represented as risk ratios (RR) with 95% confidence intervals (CI) and heterogeneity was evaluated using the I² statistic.

Results: Of 517 records screened, 13 studies were included, comprising observational studies, and randomized controlled trials. Most of the studies showed pitavastatin to be associated with a lower or no risk of NODM. Meta-analysis revealed that pitavastatin had a lower risk of NODM compared to atorvastatin (RR = 0.86, 95% CI = 0.79-0.93, p = 0.0002) and rosuvastatin (RR = 0.77, 95% CI = 0.71-0.84, p < 0.00001).

Conclusion: Pitavastatin poses a lower risk of NODM than other statins, making it a potentially safer option for patients requiring long-term statin therapy.

Protocol registration: www.crd.york.ac.uk/prospero identifier is CRD42022371741.

查看原文本刊更多论文

匹伐他汀与阿托伐他汀和罗苏伐他汀相比的新发糖尿病风险：系统回顾和荟萃分析。

背景：他汀类药物与新发糖尿病（NODM）的风险有关：他汀类药物与新发糖尿病（NODM）的风险有关。阿托伐他汀和罗苏伐他汀通常与 NODM 有关，而匹伐他汀的风险可能较低。本系统综述和荟萃分析（SRMA）评估了匹伐他汀与阿托伐他汀和罗苏伐他汀相比对NODM的影响：我们使用 PubMed、CENTRAL、EMBASE 和 ClinicalTrials.gov 进行了系统的文献检索。两位作者独立筛选研究，使用乔安娜-布里格斯研究所、纽卡斯尔-渥太华和苏格兰校际指南网络检查表评估偏倚风险，并提取数据。分析使用RevMan 5.4.1进行，结果以风险比（RR）和95%置信区间（CI）表示，并使用I2统计量评估异质性：在筛选出的 517 条记录中，共纳入了 13 项研究，包括观察性研究和随机对照试验。大多数研究表明，匹伐他汀与较低的非结节性动脉粥样硬化风险相关，或者没有相关风险。元分析显示，与阿托伐他汀相比（RR = 0.86，95% CI = 0.79-0.93，P = 0.0002），匹伐他汀与罗苏伐他汀相比（RR = 0.77，95% CI = 0.71-0.84，P = 0.0002），匹伐他汀发生 NODM 的风险较低：与其他他汀类药物相比，匹伐他汀发生NODM的风险较低，因此对于需要长期接受他汀类药物治疗的患者来说，匹伐他汀可能是一种更安全的选择。协议注册：www.crd.york.ac.uk/prospero 识别码为CRD42022371741。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Pharmacology PHARMACOLOGY & PHARMACY-

CiteScore

7.30

自引率

2.30%

发文量

127

期刊介绍： Advances in drug development technologies are yielding innovative new therapies, from potentially lifesaving medicines to lifestyle products. In recent years, however, the cost of developing new drugs has soared, and concerns over drug resistance and pharmacoeconomics have come to the fore. Adverse reactions experienced at the clinical trial level serve as a constant reminder of the importance of rigorous safety and toxicity testing. Furthermore the advent of pharmacogenomics and ‘individualized’ approaches to therapy will demand a fresh approach to drug evaluation and healthcare delivery. Clinical Pharmacology provides an essential role in integrating the expertise of all of the specialists and players who are active in meeting such challenges in modern biomedical practice.